REVIVA PHARMACEUTICALS HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $5.94M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | – | $-0.19 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | – | $-0.46 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | – | $-0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | $-0.25 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 15, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | During market hours | – | – | – |
Press releases
Announcements Reviva Pharmaceuticals filed with the SEC
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces Letter to Shareholders
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the Market Under Nasdaq Rules
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Announces Letter to Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K